Drugs /

vodobatinib

Back to Drugs List
Associated Genetic Biomarkers

Overview

NCI Definition [1]:
An orally bioavailable, Bcr-Abl tyrosine kinase inhibitor (TKI), with potential antineoplastic activity. Upon administration, Bcr-Abl kinase inhibitor K0706 selectively targets and binds to the Bcr-Abl fusion oncoprotein, including various Bcr-Abl mutant forms, such as those with the 'gatekeeper' resistance mutation T315I. This inhibits proliferation of Bcr-Abl-expressing tumor cells. The Bcr-Abl fusion protein is an aberrantly activated tyrosine kinase produced by certain leukemia cells. T315I, an amino acid substitution where threonine (T) has been mutated to isoleucine (I) at position 315 in the tyrosine-protein kinase ABL1 portion of the Bcr-Abl fusion protein, plays a key role in resistance to certain chemotherapeutic agents and its expression is associated with poor prognosis.

Clinical Trials

View Clinical Trials for vodobatinib

Vodobatinib has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating vodobatinib, 1 is phase 1/phase 2 (1 open).

Chronic myeloid leukemia is the most common disease being investigated in vodobatinib clinical trials [2].

Drug Details

Synonyms [2]:
k0706, sun-k0706, sun-k706, sun k706, bcr-abl kinase inhibitor k0706
Drug Categories [2]:
Tyrosine kinase inhibitors
Drug Target(s) [2]:
ABL1
NCIT ID [1]:
C132173

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.